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Abstract
Since the olden times, infectious diseases have largely affected human existence. The newly emerged infections are exces-
sively caused by viruses that are largely associated with mammal reservoirs. The casualties of these emergencies are signifi-
cantly influenced by the way human beings interact with the reservoirs, especially the animal ones. In our review we will 
consider the evolutionary and the ecological scales of such infections and their consequences on the public health, with a 
focus on the pathogenic influenza A virus. The nutraceutical properties of fungal and plant terpene-like molecules will be 
linked to their ability to lessen the symptoms of viral infections and shed light on their potential use in the development of 
new drugs. New challenging methods in antiviral discovery will also be discussed in this review. The authors believe that 
pharmacognosy is the “wave of future pharmaceuticals”, as it can be continually produced and scaled up under eco-friendly 
requirements. Further diagnostic methods and strategies however are required to standardise those naturally occurring 
resources.
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1 Introduction
A glimpse at the preoccupation of yet to spread pathogens, 
may suggest unfounded safety precautions, however, the 
huge public health consequences of measles, malaria, tuber-
culosis exemplified the influence of late underpinnings of 
new disease [1]. Although, not all new infections have had 
huge health problems as the above mentioned examples, the 
outbreak and the devastating effect of HIV on human popu-
lation, is an obvious counterargument of the possibility of 
novel infections impact on public health and their subse-
quent economic catastrophe [2].
The infection process of most emerging diseases involves 
two steps: introduction and adoption. Firstly, the infection 
agent invades a new host (regardless of its origin, environ-
ment, or different species), and secondly the agent’s estab-
lishment inside the host [3]. Although, first incidents of pan-
demics are thousands of years back, the emergence of new 
epidemics or the re-emergence of known infections, continue 
as the interaction between humans and animals including 
their niches increases. There are many reasons for global 
disease outbreaks, individual movements for example, can 
spread previously controlled infections in developed coun-
tries to others with poor health systems. Microbial adapta-
tion to environmental changes, such as developing resist-
ance to antibiotics—which is a consequence of antibiotics 
overuse in animal farming and food processing—increases 
the chances of the emergence of new strains of pathogens. 
Ecological changes such as deforestation, can also increase 
the likelihood of indirect contact with different types of 
insect vectors and mammalian reservoirs. The infection of 
some diseases can increase during the cold season, like influ-
enza in winter. As well as the ease in the international travel 
of goods, animals, and humans, made the transmission of 
diseases or their vectors much easier yet more difficult to 
control [4]. Above all, shortage of public health facilities, 
such as drinkable water, educational programmes and lack of 
living expense can participate largely in disease outbreak as 
 * Suhad A. A. Al-Salihi 
 Suhad.A.Ahmed@uotechnology.edu.iq
 * Fabrizio Alberti 
 f.alberti@warwick.ac.uk
1 Applied Sciences Department, University of Technology, 
Baghdad, Iraq
2 School of Life Sciences and Department of Chemistry, 
University of Warwick, Gibbet Hill Road, 
Coventry CV4 7AL, UK
 S. A. A. Al-Salihi and F. Alberti
1 3
well as the re-emerging of previously contained contagions 
[5]. Since the 1940s, the human lifespan has been greatly 
improved by the introduction into the drug discovery field 
of naturally produced fungal bioactive molecules, as well as 
of their semisynthetic derivatives and synthetic analogues 
inspired by natural products. However, nowadays we simul-
taneously face a challenging rise in antimicrobial resistance, 
and a dramatic decrease in drug innovation. The chemical 
constituents that are responsible for the bioactivities of fungi 
are mostly terpene derivatives, some of which (monoterpe-
nes and sesquiterpenes) are volatile in their nature. These 
compounds are overly broad in their pharmacokinetic spec-
trum, and often inspired structure-based drug design, par-
ticularly in oncogenic and contagious diseases. Insightful 
knowledge of the chemistry, biogenetic and biotechnology 
associated to them, will fruitfully increase the application of 
their native producers—mushroom forming fungi [6].
It is therefore important to better our understanding of the 
geographical and natural evolution of infectious diseases, as 
well as of the bioactive metabolites made by living organ-
isms such as mushroom-forming fungi, to develop new tools 
to defeat future microbial threats, through effective coordi-
nated global interactions.
2  Influenza Viruses
2.1  Evolution of Influenza Viruses
Influenza viruses are a group of microbes belonging to the 
family Orthomyxoviridae. They are negative single stranded 
RNA viruses, causing severe emerging and re-emerging res-
piratory infections in human, due to their ability to alter their 
genomes continuously (Fig. 1).
They are classified into four main types: Alpha influenza 
(A), Beta influenza (B), Gamma influenza (C) and Delta 
influenza (D) [7]. A and B are known as seasonal viruses 
or the so called “human influenza”, they mainly cause sea-
sonal flu epidemics, yet influenza type A is the only one 
that has caused influenza pandemics to date—epidemics 
develop to pandemics when new strains of microbes infect 
people and can spread globally. While type C is responsible 
for mild symptoms in human, with limited spread ability, 
type D mainly infect cattle [8]. According to proteins Neu-
raminidase (N) and hemagglutinin (H) that are attached to 
their surface, viruses can be divided into many subgroups. 
N includes 11 subtypes and H includes 18 subtypes. Nearly 
198 subtypes of influenza virus A have been predicted, of 
which 131 subtypes have been confirmed. Types that fre-
quently infect people are, influenza A(H1N1) and influenza 
A(H3N2). The latter has the tendency to change its genetic 
material rapidly. Like type A, influenza type B is classi-
fied into two subgroups; Yamagata and Victoria which are 
further divided into many subclades (Fig. 2). Cases of co-
circulation of both subgroups were reported around the 
world, however, with variable geographical distribution of 
each subgroup. Generally, the genetic material of type B is 
more stable than type A in terms of rate of changes/muta-
tions [9].
The annual infection rates of influenza A and B in humans 
range from 5 to 15%, of which children represent the higher 
percentage (nearly a third) of infection incidences. Since the 
human immune system cannot save the memory of previous 
influenza viruses for a lifetime, individuals are at risk of 
recurrent infections. This reflects the fact that the immune 
system of every adult has a history of viral infections [10].
The first detection of influenza viruses dates back to the 
sixteenth century, during the Russian influenza pandemic. 
Generally, influenza viruses transmit from their primitive 
hosts to their intermediate ones to ensure better evolution 
and subsequent transmission. Not long ago, the infection 
landscape of influenza has expanded widely to include pre-
viously unhabituated hosts such as whales, seals, and bats. 
Influenza A for example, affects a wide range of mamma-
lians including pigs, dogs, seals, cats and humans, where 
the latter become an intermediate host for numerous viruses 
[11]. Viral infections largely take two routes: the first one 
is the isolated route or the unsustainable infection, where 
the microbe fails to adapt or evolve in its new host such as 
Hantavirus Pulmonary Syndrome and Ebola disease. In the 
second route the virus (e.g. influenza) adapts in the interme-
diate host, and successfully transmits to a new environment, 
Fig. 1  Structure of influenza A virus. The viral genome consists of 
eight RNA connected genes, surrounded by the lipid envelope, to 
which the neuraminidase and hemagglutinin proteins are attached in 
addition to the matrix and the membrane proteins
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leading to durable establishment that can resist any harsh 
environment posed by the end host [4]. There are many fac-
tors—viral and host—that influence an effective transmis-
sion and sustainability of any infection. Viral factors include 
the ability to produce adaptive mutation proteins, such as 
HA glycoprotein, PB2, NP and NS1 proteins. Other viral 
factors are its interconnectivity and population size. Host 
determinant factors represented by the presence of target 
receptors or the availability of innate immune response fac-
tors [12]. Avian influenza polymerase protein for example, 
has a limited influence in human infections, therefore, host-
based genetic mutation occurred within its units as a result 
of natural evolution, leading to successful adaptation in 
human host [13].
2.2  Pathogenic Properties of Influenza Viruses
Almost all human respiratory infections come from influ-
enza viruses, which have been around since the middle ages. 
They infect infants, people with chronic diseases, causing 
them high illness and demise. For example, in 1957 in a 
seasonal epidemic of influenza A, nearly two hundred thou-
sand Americans were hospitalized, of which 15% died [14]. 
Historically, every decade, influenza viruses’ pandemics 
emerge to infect more than half of the world population of 
which 1–2% die. On the other hand, influenza B and C, cause 
periodic epidemics and endemics with no pandemic records 
to date [7]. In terms of pathogenicity, influenza A, has the 
riskiest consequences on human health. However, associated 
health conditions (bacterial pneumonias) of infected popula-
tion, seems to vary from infections to infections. The 1918 
influenza pandemic for example, has caused high fatality 
frequency in young adults compared to elderly people, con-
trasting the two previous pandemics, where high mortality 
rate occurred in elder people and cases with chronic disease 
history [15]. The recent outbreak of coronavirus (COVID-
19) makes revising previous influenza pandemics valuable. 
Largely, influenza viruses adapt to new environments via 
changing their surface proteins. These changes are either 
accumulative or straightway. The former occurs due to lim-
ited mutations in hemagglutinin (HA) and neuraminidase 
(NA) antigens [16]. Accumulative changes happen every 
time the virus replicates, and normally produce types that 
are closely related to the original one, therefore they have 
analogous antigenic properties, that trigger similar response 
from the host immune system, resulting in cross protection. 
However, over time this process can result in strains that are 
antigenically diverse. A small mutation in one important 
domain that has a huge impact on virus antigenic properties, 
can lead to antigenic deviation. This will change the virus to 
the point that the body’s immune system cannot recognize 
these newer antigens, and ultimately become susceptible to 
infection again. This is one of the main reasons why one 
can be infected with influenza virus many times [17]. On 
the other hand, straightway changes or shift changes that 
cause the creation of novel NA and HA proteins, resulting in 
newer types of influenza A. Such shifts happen when viruses 
from different hosts (e.g. mammalians) acquire new viru-
lence ability to infect the human body, which has no immune 
defence against such virus types due to differences in their 
antigenic proteins. The H1N1 virus pandemic in 2009 is an 
example of this sort of shift, when it moved from its original 
host swine to humans. However, such intraspecies changes 
are less frequent compared to the interspecies ones [18, 19].
However, unfortunately, very few analyses concerning 
fatal cases of H5N1 have been published so far. One study 
demonstrated that the fatality of H5N1 is due to the unique 
hypercytokinemia, another study proposed the ability of 
H5N1 to replicate outside the respiratory paths [20]. How-
ever, the possibility of other pathological reasons remains 
unclear.
Fig. 2  Main two causes of human seasonal flu; influenza viruses A & B. These are further classified into groups and subgroups
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3  The Potential Role of Terpenoid Natural 
Products in Viral Infection Treatment
Although recent flu epidemics were less incurable compared 
to past epidemics, there is still an urgent need to search for 
new approaches to prevent flu pandemics, especially the 
ones caused by the influenza A. Unlike bacteria, viruses 
cannot reproduce in the absence of a living host. Once they 
are inside the host cell, they hijack its replication machinery, 
and some of them start replicating, then they eventually burst 
open the cell and infect more host cells [21]. Targeting the 
virus replication is easy, meanwhile, avoiding the disruption 
of the host cell replication is the hard process. One effective 
way would be the synthesis of multitarget molecules, that 
can inhibit multiple phases of the virus life cycle [16].
Volatile natural products have shown their efficiency 
as antibacterial agents, and investigation of their antiviral 
activity is vital. The experimental improvement of influenza 
symptoms such as headache, runny nose and malaise during 
the co-use of volatile oils with synthetic medicines, suggests 
that volatile compounds can have an impact in lessening 
influenza consequent spread [22].
Generally, antiviral drugs have been designed to stop 
viruses from inserting their viral genomes into the host cell, 
as well as to avert the new copies from infecting other host 
cells. Ganciclovir and acyclovir, for example, are designed 
to inhibit the synthesis of the viral DNA of cytomegalovi-
rus and simplex virus, respectively [23, 24]. However, those 
DNA inhibitors are not effective against viral RNA such as 
hepatitis and influenza viruses. Besides that, many species 
of influenza virus have developed resistance to the currently 
used medications, as such, more viral genome specific drugs 
are needed, to kill a specific virus, or control the spread of 
similar ones [25]. Aromatics or natural oils are a chemi-
cally diverse group of bioactive substances; thus, they have 
the potential to become novel antivirals, that can effectively 
interrupt virus development or block their invasion [26, 27].
3.1  Fungal Antivirals
Over the last decades, tens of thousands of metabolites have 
been described from the fungal kingdom, many of which 
possess diverse medicinal properties including antibacte-
rial, antifungal, antiviral, and antitumor. However, fungal 
natural products with antiviral properties were less lengthily 
investigated. Nevertheless, the number of fungal antiviral 
studies is gradually increasing, particularly, those that are 
related to medicinal mushrooms [28]. Although, many of the 
selected molecules in the below table (Table 1) have a wide 
range of bioactivities, we focused our scope on their antiviral 
properties. The described chemicals, belong to an array of 
fungal terpenes, and they were selected through an extensive 
literature search. 6-epi-ophiobolin K is a member of the 
ophiobolins group of sesterterpenoids, having a molecular 
formula  C25H36O3. It is produced by a strain of a Neosar-
torya sp, and it showed HIV-1-integrase inhibitory activity 
[29]. 6β,9α-dihydroxy-14-p-nitrobenzoylcinnamolide is a 
rare sesquiterpenoid molecule (formula  C22H25NO8) with 
antiviral activity against H3N2 and EV71, and it is pro-
duced by the marine-derived ascomycete fungus Aspergillus 
ochraceus [30]. Equisetin is a tetramic acid like compound 
isolated from Fusarium equiseti, with substituted aliphatic 
bicyclic ring, having molecular formula  C22H31NO4 and 
shows inhibition activity on HIV-1 integrase [31]. Integra-
cide A  (C32H50O8S) and integracide D  (C36H58O8) also show 
inhibition of the HIV-1 integrase [32], and are tetracyclic 
triterpenoids made by Fusarium sp. The oblongolides are 
tricyclic compounds derived from the fungus Phomopsis sp. 
BCC 9789 and display anti-HSV-1 activity [33]. The last 
two compounds derived from ascomycete fungi included in 
Table 1 are stachyflin, with molecular formula  C23H31NO4, 
and stachybotrylactam,  C23H31NO4, sesquiterpene deriva-
tives isolated from the Stachybotrys sp. that exhibit inhibi-
tion on HSV-1, H1N1 and H2N2 [34–36]. The table also 
includes molecules characterised from basidiomycete spe-
cies such as the sesquiterpene Illudin S,  C15H20O4, which 
is a highly reactive molecule that can bind to the DNA 
and cause its damage and was first isolated from the Jack 
o’ Lantern mushroom Omphalotus illudens, showing inhi-
bition of HSV-1 [37]. The bis-sesquiterpene agrocybone, 
molecular formula  C30H36O5, has an eight-ring structure 
derived from the binding of two molecules of illudane via 
Diels–Alder reaction and shows weak antiviral properties 
against the respiratory syncytial virus (RSV) [38]. Triterpe-
noids with antiviral activity have been abundantly described 
as being isolated from the fruiting bodies of Ganoderma 
lucidum mushrooms, such as the lanosterol derived triter-
penoid ganoderic acid Y, molecular formula  C30H46O3, as 
well as many closely related triterpenoids, including the oxi-
dized lanostane triterpenoids lucidenic acid P,  C29H44O7, 
lucidumol B,  C30H50O3, and ganolucidic acid A,  C30H44O6 
[39–41]. Ganoderma colossum produces the lanostane trit-
erpenes schisanlactone A, formula  C30H40O4, colossolactone 
E,  C32H54O6, and colossolactone V,  C35H54O9, which show 
anti-HIV-1 protease activity [42]. Another species of the 
Ganoderma genus, Ganoderma pfeifferi, produces antivi-
ral triterpenoids such as lucidadiol,  C30H48O3, ganoderone 
A, with molecular formula  C30H46O3, applanoxidic acid G, 
 C30H40O8, and lucialdehyde B,  C30H44O3 [43, 44].
Bioactive compounds are organic molecules with nor-
mally small molecular weight that can be produced by both 
Ascomycetes and Basidiomycetes. Literature reports on 
fungal antiviral sources reveal that most known bioactive 
molecules have been isolated from Ascomycetes and Basidi-




































































































































































































































































































































































































































































































































































































































































































































































































































two phyla as producers of therapeutic compounds [45–48]. 
The studies indicated also that the biosynthetic gene clusters 
of the bioactive metabolites’ dominance are generally lower 
in number in basidiomycetes compared to the ascomycetes. 
However, this difference reflects the bias from the use of 
different techniques and tools in isolating and characterising 
the bioactive compounds, and not their genuine productiv-
ity of biologically active metabolites [49]. Current reports 
on fungal diversity prediction, suggested that less than 10% 
of fungal species are described, which again demonstrates 
the great potential of fungi as a source of antivirals [50]. 
Above that, medicinal mushrooms played an important role 
in natural remedies, their healing power has been subjected 
to vast scientific research, such as the edible mushroom 
shiitake. Many other species of mushroom-forming fungi 
exhibited potential to produce natural antivirals. Reports on 
mushrooms bioactivities, linked their ability in defeating 
viral infections to the presence of two types of chemicals: 
polysaccharides and terpene like compounds [51]. However, 
other types of biologically important molecules have been 
reported from mushrooms, implying the potential content 
of structurally diverse biomolecules that are awaiting dis-
covery [52]. Historically, terpene derivatives are one of the 
most widespread naturally occurring products, that are pre-
dominantly found in the form of aromatic oils. Such prod-
ucts were mainly used, for instance, for religious reasons in 
the olden Egypt. Camphor (a terpene isolated from essen-
tial oils of camphor tree) for example, was first introduced 
to Europe by Arabian traders ten centuries ago. In 1818 
researchers were able to analyse turpentine oils and then 
propose the term “terpene” instead of camphor, which was 
used to describe extracted crystalline oxygenated molecules 
from essential oils. Further analysis by other researchers has 
resulted in the description of the building block “isoprenic” 
of this molecule [53]. The role of mevalonic acid in choles-
terol biosynthesis and its incorporation in the synthesis of 
many terpene compounds was defined in 1956. Following 
this, thousands of terpenoids were structurally and function-
ally characterised. Apart from their antimicrobial activities, 
terpenes have also been reported as hormones and photosyn-
thetic pigments [54].
3.2  Aromatic Natural Oils
Research on essential oils extracted from plants, demon-
strated the dominance of terpene-like compounds. particu-
larly monoterpenes and triterpenes, as they represented 
more than 95% of the chemical constituents of those oils 
[55]. We, therefore, further searched for promising anti-
viral terpenes characterised in plants and presented them 
in Table  2. These include eugenol (molecular formula 
 C10H12O2), a volatile phenolic compound with antiviral 
properties, which represents an essential constituent of 
clove oil [56, 57]. Germacrone, formula  C15H22O, is the 
sesquiterpene constituent of the essential oil of many glob-
ally distributed plants and shows inhibition activity on the 
influenza virus [58, 59]. Patchouol, formula  C15H26O, is a 
sesquiterpene alcohol mainly found in patchouli plant leaves, 
and has shown promising results as an inhibitor of influenza 
viruses [59–62]. Interestingly, this compound is also used 
as a precursor in the synthesis of the anticancer compound 
taxol. β-santalol, formula  C15H24O, is another example of 
a sesquiterpene type compound, found in Santalum album, 
in which it represents one fifth of the total plant essential 
oil [63]. Terpinen-4-ol and α‐terpineol, both with chemi-
cal formula  C10H18O, are components of the essential oil of 
the tea tree and many other aromatic plants, and they show 
antiviral activity [64–66]. Terpinolene belongs to the group 
of monoterpenes, with chemical formula  C10H16, and can be 
naturally sourced from different plants, such as cardamom.
Aromatic natural oils are bio-generated via differentiated 
pathways in plants, fungi as well as some species of bacteria. 
Their main components belong to the highly variable fam-
ily of natural products—terpenes—including derivatives of 
ketones, alcohols, phenols, esters and aldehydes. Over the 
last decade, volatile chemicals regained interest as sources 
of new antimicrobials and anticancer compounds. Although, 
they were mainly used against carcinogenic and bacterial 
infections, their potential anti-inflammatory, antioxidant and 
immunomodulatory are reasonably investigated [56, 67].
Essential oils contain many functioning compounds, 
including mono- and sesquiterpenes. Many of those vola-
tile substances can be competently used in the medication 
of different types of cancers, either as antitumor or sup-
portive compounds [68]. The awareness of terpene derived 
compounds as potential antitumors started when clinical 
researches showed their distinguished biological activity and 
their non-toxic impact on human’s normal cells, as many 
of them have been stated as Generally Regarded As Safe 
(GRAS) substances, which represents key criteria for their 
use for antibiotic discovery [69].
Terpenes are a large class of natural metabolites that 
comprise over two thirds of all known secondary metab-
olites. They are biosynthesised by most living organisms 
including plants, fungi and bacteria, however many of these 
compounds investigated by scientists are from plants or 
mushroom-forming fungi [70]. Compared to the current 
knowledge of chemicals produced by fungi, little is known 
about their synthesis and function—especially for terpenes. 
The antagonistic or synergistic interactions of those natural 
substances with other chemical or biological elements, can 
negatively influence their therapeutic properties. It is, there-
fore, important to use well-defined molecules in terms of 
organism, enzymes, biosynthesis routes and activity. Since 
those biologically interesting terpenes are produced in small 
quantities by their native organisms, there is a reasonable 
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need to thoroughly investigate their synthesis via combi-
natorial pathways—as classical chemical synthesis proved 
ineffective in terms of purity and environmental impact of 
catalysts—and in the presence of selective enzymes and 
affordable simple terpenes, such as pinene and limonene 
[43, 71–73].
3.3  Biotechnological Strategies for Drugs Synthesis
Normally, terpene biosynthetic genes are customarily 
located next to each other in one biosynthetic gene cluster, 
easing their exploitation and manipulation to produce bio-
active compounds with desired quality and quantity [74]. 
Historically, more than half of the drugs in use, are sourced 
from natural substances or their derivatives. With the recent 
advancements in genomic analysis and analytical tools, new 
strategies and methods have been utilised for the exploitation 
of naturally synthesised compounds that are of biotechno-
logical importance [75]. The main aim of using such tech-
niques was to predict the genes encoding molecules with 
novel bioactivity. These techniques have further established 
the fact that the capability of mushroom forming fungi to 
synthesise bioactive molecules has been overlooked. They 
have also revealed the presence of the so called “cryptic” 
or “orphan” biosynthetic gene clusters [76]. The pressing 
need to produce new antibiotics due to the non-stop increase 
in antimicrobial resistance and the decline in efficiency of 
accessible drugs, highlights the importance of using unprec-
edented techniques such as genome mining in drug discov-
ery. This approach can simplify the biosynthesis of biologi-
cally engineered compounds via reducing their commercial 
production and use [77]. This genome mining method can 
be applied in many different ways. One way is the detec-
tion of compound’s coding genes, through “target directed 
genome mining”, which mainly consists in the identifica-
tion of biosynthetic gene clusters with unknown function 
in terms of the corresponding molecule(s) produced [78]. 
Another way is “the one strain many compounds approach”, 
this method can be used to induce the expression of cryptic 
genes through controlled alteration of growth conditions. 
Many silent metabolic pathways were activated using such 
technique, including activation of the biosynthesis of poly-
peptides and polyketides with pharmaceutical applications 
[79, 80]. Metabolism regulation can also be manipulated to 
enhance the production of secondary metabolites with novel 
bioactivity. These treatments involve the use of chemicals or 
small organic molecules to modify or deregulate metabolic 
processes through the inhibition of fatty acids [81]. Exam-
ples of other techniques used concurrently with genome 
mining-based studies are the heterologous expression of 
biosynthetic gene clusters that synthesise known bioactive 
molecules. These reconstructed routes ensure the production 
of pure and easily identifiable intermediates and eliminate 
unusable by-products. Despite that many terpenes with anti-
microbial activity have been described, many more with 
potential unique derivatives are awaiting discovery [82, 83].
4  Conclusions
Even though influenza viruses are of relatively old ori-
gins and very contagious, the currently used antivirals are 
undoubtedly limited in terms of their bioactivity spectrum 
and sources. What makes things even more concerning and 
further intensifies the need for new strategies in virucide dis-
covery, is the constant increase in antimicrobial resistance. 
Typical antibiotic discovery was and still involves the isola-
tion, characterisation, and testing methods against panels 
of pathogenic bacteria, without considering the presence of 
other life-threatening germs, which are viruses in this case. 
Lately, several literature reports described the antiviral activ-
ity of a variety of volatile compounds against some viruses 
including influenza. We therefore attempted to provide a 
brief outline on influenza virus structure, evolution, patho-
genicity and then suggest terpenes as potential sources to 
develop antivirals. Our literature search showed that viruses 
can be virulent and destructive in many levels and difficult 
to control unless urgent innovative policy is made in the 
drug discovery field. It also highlighted terpenes as potential 
antivirals due to the natural sustainability they demonstrated 
when tested against many viruses.
The recent advances in genetic tools, molecules struc-
ture modelling, and large-scale screening, established the 
guidelines for the discovery of novel antibiotics against 
infectious diseases. Current strategies involve, but are not 
limited to, two approaches. One is to characterise or improve 
drugs against known microbes. Ideally this method can be 
expanded to involve different types of viruses including the 
drug resistant ones. Second, is the validation of new targets 
in both the host and the virus, to accordingly develop novel 
classes of molecules, via either structure-based molecule 
interaction, or host transport machineries. The viral poly-
merase, for example, is an internal protein that can be fur-
ther exploited according to its structure interaction with new 
molecules. Targeting the transportation system of the host 
cell, it can also provide a new avenue for virucide develop-
ment, especially for viral RNPs, however, potential intrusion 
with the metabolic system of the host should be considered.
Undoubtedly, current computational genome sequenc-
ing, have effectively pushed the medical search generally 
and infectious disease search particularly, towards further 
understanding of the interaction between the microbial or 
viral communities and the human body, and determine their 
virulence or symbiosis at the molecular level. However, 
despite this progress in the genomic era, infectious diseases 
still cause high frequency of illness and mortality among 
Naturally occurring terpenes
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populations, especially in the developing countries. It is 
therefore vital for those countries to strengthen the input of 
bioinformatics in such field of research, through more well-
designed training, internship courses and collaboration with 
more developed specialised institutions around the globe, to 
help to control the spread of contagious diseases worldwide.
Another way that bioinformatics has contributed to the 
field of infectious diseases, was the development of a new 
era of bioactive natural products research, through linking 
many bioactive natural products to their associated biosyn-
thetic gene clusters and corresponding enzymes. Although 
this approach has proven to be effective in identifying bio-
active molecules and the BGCs that are associated to them, 
they are still in their infancy and represent a new shift in sus-
tainable drug discovery, especially for plants and animals.
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